<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="144682">
  <!-- This xml conforms to an XML Schema at:
    http://clinicaltrials.gov/ct2/html/images/info/public.xsd
 and an XML DTD at:
    http://clinicaltrials.gov/ct2/html/images/info/public.dtd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on June 04, 2014</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>http://clinicaltrials.gov/show/NCT02001285</url>
  </required_header>
  <id_info>
    <org_study_id>HJKim2</org_study_id>
    <nct_id>NCT02001285</nct_id>
  </id_info>
  <brief_title>Effect-site Concentration of Remifentanil for Blunting Hemodynamic Responses to Double-lumen Endobronchial Intubation</brief_title>
  <official_title>Comparison of the Effect-site Concentration of Remifentanil for Blunting Hemodynamic Responses to Ordinary Tracheal and Double-lumen Endobronchial Intubation During Propofol-remifentanil Total Intravenous Anesthesia</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Jeju National University School of Medicine</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Jeju National University School of Medicine</source>
  <oversight_info>
    <authority>Korea: Food and Drug Administration</authority>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study is the comparison of the effect-site concentration of remifentanil
      for blunting hemodynamic responses to ordinary tracheal and double-lumen endobronchial
      intubation during propofol-remifentanil total intravenous anesthesia.
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date>October 2013</start_date>
  <completion_date type="Anticipated">September 2015</completion_date>
  <primary_completion_date type="Anticipated">September 2015</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <study_design>Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Prevention</study_design>
  <primary_outcome>
    <measure>arterial blood pressure</measure>
    <time_frame>Change from baseline in arterial blood pressure at intubation period</time_frame>
    <safety_issue>Yes</safety_issue>
    <description>Arterial blood pressure will be recorded before anesthesia, after propofol infusion, after remifentanil infusion and after intubation during 3 min with 1 min interval.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>heart rate</measure>
    <time_frame>Change from baseline in heart rate at intubation period</time_frame>
    <safety_issue>Yes</safety_issue>
    <description>Heart rate will be recorded before anesthesia, after propofol infusion, after remifentanil infusion and after intubation during 3 min with 1 min interval.</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">50</enrollment>
  <condition>Intubation, Intratracheal</condition>
  <arm_group>
    <arm_group_label>Double lumen tube</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>This arm contains patients who are needed endobronchial intubation with double lumen tube for general anesthesia. After propofol infusion of effect site concentration 4 μg/ml, remifentanil infusion will be started with effect site concentration of 3.5 ng/ml. According to change arterial blood pressure and heart rate from baseline value, next remifentanil concentration will be regulated using up-and-down method. Step size of dose is 0.5 ng/ml.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>single lumen tube</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>This arm contains patients who are needed endotracheal intubation with single lumen tube for general anesthesia. After propofol infusion of effect site concentration 4 μg/ml, remifentanil infusion will be started with effect site concentration of 3.5 ng/ml. According to change arterial blood pressure and heart rate from baseline value, next remifentanil concentration will be regulated using up-and-down method. Step size of dose is 0.5 ng/ml.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Remifentanil</intervention_name>
    <description>During intubation, remifentanil will be infused to prevent change arterial blood pressure and heart rate.</description>
    <arm_group_label>Double lumen tube</arm_group_label>
    <arm_group_label>single lumen tube</arm_group_label>
    <other_name>Ultiva (TM)</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Adult patient who is needed intubation for general anesthesia

        Exclusion Criteria:

          -  patient who is anticipating difficult airway

          -  patient who takes any drug to influence this study

          -  cardiovascular disease, renal disease, liver disease
      </textblock>
    </criteria>
    <gender>Both</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>60 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_contact>
    <last_name>Hyun Jung Kim, MD, PhD</last_name>
    <phone>82-64-717-2026</phone>
    <email>hjanesthesia@empas.com</email>
  </overall_contact>
  <location>
    <facility>
      <name>Jeju National University Hospital</name>
      <address>
        <city>Jeju-si</city>
        <state>Jeju Special Self-Governing Province</state>
        <zip>690-767</zip>
        <country>Korea, Republic of</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Hyun Jung Kim, MD, PhD</last_name>
      <phone>82-64-717-2026</phone>
      <email>hjanesthesia@empas.com</email>
    </contact>
  </location>
  <location_countries>
    <country>Korea, Republic of</country>
  </location_countries>
  <verification_date>November 2013</verification_date>
  <lastchanged_date>November 27, 2013</lastchanged_date>
  <firstreceived_date>October 28, 2013</firstreceived_date>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Jeju National University School of Medicine</investigator_affiliation>
    <investigator_full_name>Hyun Jung Kim</investigator_full_name>
    <investigator_title>Assistant professor</investigator_title>
  </responsible_party>
  <keyword>remifentanil</keyword>
  <is_fda_regulated>No</is_fda_regulated>
  <has_expanded_access>No</has_expanded_access>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Remifentanil</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                -->
</clinical_study>
